Skip to main content
Glama

Midgard Finance drug data

get_trial

One trial's design, by NCT number or by trial key (SURMOUNT-1, scale, redefine-1).

Input Schema

NameRequiredDescriptionDefault
identifierYes

Schema Changelog

Changes observed during successful MCP inspections.

  1. First observed

TDQS

B3.2/5.0
Behavior2/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

No annotations are provided, so the description carries the full burden, and it discloses almost no behavior: nothing about error handling for unknown trials, whether aliases are case-insensitive, or what 'design' actually contains. The one behavioral clue is that alternative identifier forms (NCT number or trial key) are accepted, but that is input-level, not behavioral context about the call.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

One sentence, zero filler, with the resource and the accepted identifier forms front-loaded. Nothing is wasted and nothing is buried.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness3/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a single-parameter read tool with no output schema and no annotations, the description is minimally adequate: an agent knows what it fetches and how to identify the trial. It leaves open what 'design' returns and how failures surface, which for a tool with no annotation safety net is a meaningful residual gap.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 0% and the single parameter is just named 'identifier', but the description compensates well by enumerating the accepted forms (NCT number or trial key) with three concrete examples (SURMOUNT-1, scale, redefine-1). It is not exhaustive (no statement on case sensitivity or ambiguity when multiple trials match), but it does real work the schema does not.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose4/5

Does the description clearly state what the tool does and how it differs from similar tools?

States a specific verb+resource ('get' a 'trial') and narrows the return to the trial's 'design', which implicitly distinguishes it from siblings like get_adverse_events or compare_efficacy. It does not name a sibling explicitly, keeping it below a 5.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines2/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

There is no statement of when to use this tool versus alternatives such as compare_efficacy, get_adverse_events, or search_drugs. The only guidance is about input format, not selection context or preconditions.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

Resources